Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.

Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
复制标题

DOI:
10.1002/alz.12406
复制
发表时间:
2022-04
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
通讯作者:
--
中科院分区:
其他
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

我们的目的是为自动化 Elecsys 阿尔茨海默病 (AD) 脑脊液 (CSF) 生物标志物提供切点。在 Mayo Clinic 衰老研究 (n = 804) 和 Mayo Clinic 阿尔茨海默病研究中心 (n = 70) 参与者中评估了 Elecsys 淀粉样蛋白 β 42 (Aβ42)、总 tau (t-tau)、过度磷酸化 tau (p-tau) 以及 t-tau/Aβ42 和 p-tau/Aβ42 比率的切点。 t-tau/Aβ42 和 p-tau/Aβ42 比率与正常/异常淀粉样蛋白正电子发射断层扫描 (PET) 的一致性百分比高于单个 CSF 标记物。基于接受者操作特征 (ROC) 的切点,t-tau/Aβ42 为 0.26 (0.24–0.27),p-tau/Aβ42 为 0.023 (0.020–0.025)。来自其他队列的比率削减点在我们队列中的表现与我们自己的队列一样好。单个生物标志物的诊断特性较差,并且在阳性和阴性百分比一致性(PPA 和 NPA)方面结果变化更大。 CSF t-tau/Aβ42 和 p-tau/Aβ42 比率是非常可靠的 AD 指标。对于单个生物标志物,预期用途应决定选择哪个切点。
We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers. Cut points for Elecsys amyloid beta 42 (Aβ42), total tau (t‐tau), hyperphosphorylated tau (p‐tau), and t‐tau/Aβ42 and p‐tau/Aβ42 ratios were evaluated in Mayo Clinic Study of Aging (n = 804) and Mayo Clinic Alzheimer's Disease Research Center (n = 70) participants. The t‐tau/Aβ42 and p‐tau/Aβ42 ratios had a higher percent agreement with normal/abnormal amyloid positron emission tomography (PET) than the individual CSF markers. Reciever Operating Characteristic (ROC)‐based cut points were 0.26 (0.24–0.27) for t‐tau/Aβ42 and 0.023 (0.020–0.025) for p‐tau/Aβ42. Ratio cut points derived from other cohorts performed as well in our cohort as our own did. Individual biomarkers had worse diagnostic properties and more variable results in terms of positive and negative percent agreement (PPA and NPA). CSF t‐tau/Aβ42 and p‐tau/Aβ42 ratios are very robust indicators of AD. For individual biomarkers, the intended use should determine which cut point is chosen.
elecsys(®)淀粉样β(1-42)测定阿尔茨海默氏病的临界值的推导。
DOI: 10.1016/j.dadm.2018.07.002
发表时间: 2018
期刊: Alzheimer's & dementia (Amsterdam, Netherlands)
影响因子: --
作者:
Shaw LM;Waligorska T;Fields L;Korecka M;Figurski M;Trojanowski JQ;Eichenlaub U;Wahl S;Quan M;Pontecorvo MJ;Lachno DR;Talbot JA;Andersen SW;Siemers ER;Dean RA
通讯作者: Dean RA
DOI: 10.1016/j.jalz.2011.03.005
发表时间: 2011-05
期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子: --
作者:
McKhann GM;Knopman DS;Chertkow H;Hyman BT;Jack CR Jr;Kawas CH;Klunk WE;Koroshetz WJ;Manly JJ;Mayeux R;Mohs RC;Morris JC;Rossor MN;Scheltens P;Carrillo MC;Thies B;Weintraub S;Phelps CH
通讯作者: Phelps CH
DOI: 10.1186/s13195-016-0233-7
发表时间: 2017-02-14
影响因子: 9
作者:
Bertens, Daniela;Tijms, Betty M.;Visser, Pieter Jelle
通讯作者: Visser, Pieter Jelle
DOI: 10.1016/j.jalz.2019.03.016
发表时间: 2019-07-01
影响因子: 14
作者:
Lowe, Val J.;Lundt, Emily S.;Murray, Melissa E.
通讯作者: Murray, Melissa E.
DOI: 10.1016/j.clinbiochem.2013.12.024
发表时间: 2014-03-01
影响因子: 2.8
作者:
Teunissen, Charlotte E.;Tumani, Hayrettin;Mollenhauer, Brit
通讯作者: Mollenhauer, Brit